Preferred Label : Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006;
NCIt synonyms : Autologous CAR-T Cells PRGN 3006; Autologous Anti-CD33 CAR-T Cells PRGN-3006;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to co-express
three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric
antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD33, a membrane-bound
IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic
activities. Upon introduction of the autologous anti-CD33 CAR-mbIL15-safety switch
T-cells PRGN-3006 into the patient, the T-cells target and bind to CD33-expressing
tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33,
a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic
stem cells and overexpressed on a variety of cancer cell types, including acute myeloid
leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.
IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived
CD8 memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through
sustained IL-15 signaling, improves T-cell persistence and potentiates the immune
response against tumor cells. The safety switch can promote selective elimination
of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion
variant and safety switch transgenes into T-cells without the need for viral vectors
and accelerates the manufacturing process.;
Molecule name : PRGN 3006; PRGN-3006;
NCI Metathesaurus CUI : CL969928;
Origin ID : C160847;
UMLS CUI : C5205604;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
